alpha synuclein alphasyn or snca inhibitor pipeline insight

DelveInsight’s, “Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2025,” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Alpha-Synuclein (alphaSyn or SNCA) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• Global coverage

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor Understanding

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor: Overview

α-syn is an abundant 14 kDa protein consisting of 140 amino acids and comprised of three domains: an N-terminal lipid-binding alpha-helix; a non-amyloid-component (NAC); and an acidic C-terminal tail. The N-terminal domain of α-syn is characterized by a series of seven 11-residue imperfect repeats, each based upon a highly conserved KTKEGV hexameric motif that is also observed in the α-helical domain of apolipoproteins. Parkinson’s disease (PD) is one of the most common neurodegenerative disorders with a global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both the sporadic and familial forms of the disease. Moreover, alpha-synuclein is present in Lewy-bodies, the neuropathological hallmark of PD, and the protein and its aggregation have been widely linked to neurotoxic pathways that ultimately lead to neurodegeneration. Such pathways include autophagy/lysosomal dysregulation, synaptic dysfunction, mitochondrial disruption, and endoplasmic reticulum (ER) and oxidative stress. Alpha-synuclein has not only been shown to alter cellular pathways but also to spread between cells, causing aggregation in host cells. Therapeutic approaches will need to address several, if not all, of these angles of alpha-synuclein toxicity.

 

"Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor pipeline landscape is provided which includes the disease overview and Alpha-Synuclein (alphaSyn or SNCA) Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Alpha-Synuclein (alphaSyn or SNCA) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alpha-Synuclein (alphaSyn or SNCA) Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Alpha-Synuclein (alphaSyn or SNCA) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve Alpha-Synuclein (alphaSyn or SNCA) Inhibitor.

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor Emerging Drugs Chapters

This segment of the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor Emerging Drugs

 

UCB0599: UCB Biopharma

UCB0599 is an investigational small molecule that prevents the pathological misfolding and accumulation of alpha-synuclein, a protein which plays a role in Parkinson’s disease (PD) pathology. Inhibition of alpha-synuclein misfolding has the potential to slow down the progression of PD. UCB0599 belongs to a series of molecules discovered by Neuropore, which was in-licensed by UCB in 2014. It is currently in Phase II stage of development.

 

Prasinezumab: Prothena Corporation/Roche

Prasinezumab is a first-in-class therapeutic with the goal of reducing clinical decline in Parkinson’s disease. Prasinezumab targets α-synuclein and is designed to block the cell-to-cell transmission of the aggregated pathogenic forms of α-synuclein that are the cause of Parkinson’s disease, thereby slowing clinical decline. Prasinezumab is currently in Phase IIb PADOVA study and ongoing long term extension of Phase II PASADENA study. Both studies are being conducted by the partner, Roche.

Further product details are provided in the report……..

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Alpha-Synuclein (alphaSyn or SNCA) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Alpha-Synuclein (alphaSyn or SNCA) Inhibitor

There are approx. 13+ key companies which are developing the therapies for Alpha-Synuclein (alphaSyn or SNCA) Inhibitor. The companies which have their Alpha-Synuclein (alphaSyn or SNCA) Inhibitor drug candidates in the most advanced stage, i.e. Phase II include, UCB Biopharma.

Phases

DelveInsight’s report covers around 13+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha-Synuclein (alphaSyn or SNCA) Inhibitor therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha-Synuclein (alphaSyn or SNCA) Inhibitor drugs.

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor Report Insights

• Alpha-Synuclein (alphaSyn or SNCA) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Alpha-Synuclein (alphaSyn or SNCA) Inhibitor drugs?
• How many Alpha-Synuclein (alphaSyn or SNCA) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alpha-Synuclein (alphaSyn or SNCA) Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Alpha-Synuclein (alphaSyn or SNCA) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?